GLSI (Greenwich LifeSciences) Total Liabilities: $5.24 Mil (As of Mar. 2026)


GLSI Greenwich LifeSciences Inc GLSI
33 GF Score
Price $22.00
! 1 Warning Sign
View Full Analysis

What is Greenwich LifeSciences Total Liabilities?

Greenwich LifeSciences GLSI -7.17% 33 Total Liabilities is $5.24 Mil as of Mar. 2026. GuruFocus rates GLSI with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

Greenwich LifeSciences's Total Liabilities for the quarter that ended in Mar. 2026 was $5.24 Mil.

Greenwich LifeSciences's quarterly Total Liabilities increased from Sep. 2025 ($1.62 Mil) to Dec. 2025 ($5.83 Mil) but then declined from Dec. 2025 ($5.83 Mil) to Mar. 2026 ($5.24 Mil).

Greenwich LifeSciences's annual Total Liabilities increased from Dec. 2023 ($0.29 Mil) to Dec. 2024 ($3.19 Mil) and increased from Dec. 2024 ($3.19 Mil) to Dec. 2025 ($5.83 Mil).

Greenwich LifeSciences Total Liabilities Historical Data

* Premium members only.

The historical data trend for Greenwich LifeSciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Greenwich LifeSciences Total Liabilities Chart

Greenwich LifeSciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 0.39 0.26 0.29 3.19 5.83

Greenwich LifeSciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.44 1.69 1.62 5.83 5.24
GLSI
33GF Score
Greenwich LifeSciences Inc GLSI
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Greenwich LifeSciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Greenwich LifeSciences's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5.825+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=5.83

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=6.178-0.353
=5.83

Greenwich LifeSciences's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5.235+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=5.24

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=10.505-5.27
=5.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $5.24 Mil mean?
Greenwich LifeSciences (GLSI) has a Total Liabilities of $5.24 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Greenwich LifeSciences and its competitors.
Is Greenwich LifeSciences' Total Liabilities too high?
Greenwich LifeSciences' current Total Liabilities is $5.24 Mil. Overall, Greenwich LifeSciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Greenwich LifeSciences' Total Liabilities compare to SABS and SRZN?
Greenwich LifeSciences' Total Liabilities of $5.24 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Greenwich LifeSciences and its competitors. Greenwich LifeSciences's current Total Liabilities is $5.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Greenwich LifeSciences stock overvalued right now?
Greenwich LifeSciences (GLSI) has a current Total Liabilities of $5.24 Mil. The current Total Liabilities is $5.24 Mil. Greenwich LifeSciences' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Greenwich LifeSciences (GLSI), the current Total Liabilities is $5.24 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Greenwich LifeSciences Business Description

Address 3992 Bluebonnet Drive, Building 14, Stafford, TX, USA, 77477
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
33GF Score

Get the complete analysis for GLSI

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.00
Price